Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05739643 · ClinicalTrials.gov registry record · Phase 1
Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT
A Phase 1 study of Krabbe Disease, sponsored by Forge Biologics.
- Active
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 3
- Study locations
NCT05739643: Active Phase 1 study of Krabbe Disease, sponsored by Forge Biologics.
NCT05739643 is a Phase 1 study of Krabbe Disease that is active but no longer recruiting, run by Forge Biologics. The registered enrollment target is 9 participants, below the 417-participant average among 4 other Krabbe Disease trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05739643, a Phase 1 study of Krabbe Disease, is active but no longer recruiting, sponsored by Forge Biologics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a non-blinded, non-randomized dose escalation study of intravenous FBX-101 in which subjects will receive a single infusion of an adeno-associated virus gene therapy product, after more than 21 days of the HSCT (UCBT preferred HSCT source). Data from previously transplanted patients with infantile and late infantile Krabbe disease will be used as a comparator group.
Conditions Studied
Interventions
- BIOLOGICAL FBX-101
Study Locations (3)
California
- Children's Hospital of Orange County (CHOC) - Orange
Michigan
- University of Michigan Hospitals - Michigan Medicine - Ann Arbor
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2023-02-03 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
What the registry record for NCT05739643 still lists
NCT05739643 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 417-participant average among 4 other Krabbe Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Krabbe Disease appearing as the primary indexed condition, and to 1 intervention - of which FBX-101 is the first listed.
NCT05739643 reports a single indexed study location in California, Michigan, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05739643 about?
NCT05739643 is a clinical study titled "Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT". This is a non-blinded, non-randomized dose escalation study of intravenous FBX-101 in which subjects will receive a single infusion of an adeno-associated virus gene therapy product, after more than 21 days of the HSCT (UCBT preferred HSCT source). Data from previously transplanted patients with inf...
What is the current status of trial NCT05739643?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2023-02-03. Estimated completion is 2026-11.
What conditions does trial NCT05739643 study?
This clinical trial studies the following conditions: Krabbe Disease.
What interventions are being tested in trial NCT05739643?
The interventions under investigation include: FBX-101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05739643?
This trial is sponsored by Forge Biologics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05739643 being conducted?
This trial has 3 study locations across California, Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Krabbe Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI